Corvus Pharmaceuticals, Inc. Earnings Per Share Diluted

• Corvus Pharmaceuticals, Inc. showed an increase of +48.0% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from Corvus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2019: $0.44 (loss) per share | Q2 2019: $0.36 (loss) per share | Q3 2019: $0.33 (loss) per share | Q4 2019: $0.92 per share | Q1 2021: $0.34 (loss) per share | Q2 2021: $0.28 (loss) per share | Q3 2021: $0.24 (loss) per share | Q4 2021: $0.20 (loss) per share | Q1 2022: $0.18 (loss) per share | Q2 2022: $0.18 (loss) per share | Q3 2022: $0.32 (loss) per share | Q1 2023: $0.17 (loss) per share | Q2 2023: $0.14 (loss) per share | Q3 2023: $0.12 (loss) per share | Q1 2024: $0.12 (loss) per share | Q2 2024: $0.07 (loss) per share | Q3 2024: $0.60 (loss) per share | Q1 2025: $0.13 (loss) per share | Q2 2025: $0.10 (loss) per share | Q3 2025: $0.12 (loss) per share.
• Over the full 7 years of available data (2019 to 2025), Corvus Pharmaceuticals, Inc.'s Earnings Per Share Diluted has grown by 66.7%.
• Historical annual values: Fiscal year 2025: $0.53 (loss) per share | Fiscal year 2024: $1.02 (loss) per share | Fiscal year 2023: $0.56 (loss) per share | Fiscal year 2022: $0.89 (loss) per share | Fiscal year 2021: $1.03 (loss) per share | Fiscal year 2020: $0.20 (loss) per share | Fiscal year 2019: $1.59 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026